



A31910-I - 072874.0171
PATENT

tfw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hanash et al. Customer No.: 21003
Serial No. : 10/656,356 Examiner : Not Yet Assigned
Filed : September 5, 2003 Group Art Unit: 1641
For : ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM
MARKERS FOR CANCER

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 22, 2004

Date of Deposit

Rochelle K. Seide

Attorney Name

Rochelle K. Seide

Signature

32,300

Patent Reg. No.

December 22, 2004

Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO Form 1449 and respectfully request that the documents listed on the PTO Form 1449 be considered by the Examiner and made of record in the above-captioned application. Copies of some of the cited patent and non-U.S. references are not enclosed since they were either transmitted to the United States Patent and Trademark Office in parent application United States Ser. No. 09/370,337, now U.S. Patent No. 6,645,465, or cited by the Examiner in the prosecution of the parent case.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application and within three months of the filing date of the above-identified application. Therefore, Applicants do not believe that any fee is due in connection with the submission of this paper. However, if any such fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any such fee, or credit any overpayment, to Deposit Account 02-4777.

Respectfully submitted,



Rochelle K. Seide
Patent Office Reg. No. 32,300

30 Rockefeller Plaza - 44th Floor
New York, NY 10012-4498

Attorney for Applicants
212-408-2500

Enclosure

Form PTO-1449 U.S. Department of Commerce
(REV. 7-82) Patent and Trademark Office

Atty. Docket No.
A31910-I - 072874.0171

Serial No.
10/656,356

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

DEC 27 2004

(Use several sheets if necessary)

Applicants
Hanash et al.

Filing Date
September 5, 2003

Group Art Unit
1641

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
	5 7 4 1 6 5 4	04/21/98	Michel et al.	435	7.9	
	5 4 0 5 7 4 9	04/11/95	Polans et al.	435	7.23	
	5 3 1 6 9 1 5	05/31/94	Kraus et al.	435	7.95	

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translator Yes No
0 0 3 9 5 5 7	07/06/00	WO			
9 9 0 0 6 7 1	01/07/99	WO			

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Tockman et al., Cancer Res., 1992, 52:2711s-2718s.
	Kraus et al., Jnl. of Immunoassay, v13 (3), 1992, pp. 411-439.
	Miyachi et al., "Autoantibody to a Nuclear Antigen in Proliferating Cells", vol. 121, No. 6, Dec. 1978, pp. 2228-2234.
	Bachvaroff et al., "Appearance of cytoskeletal components on the surface of leukemia cells and of lymphocytes transformed by mitogens and Epstein-Barr virus", Proc. Natl. Acad. Sci. USA, vol 77, No. 8, Aug. 1980, pp. 4979-4983.
	Crawford et al., "Detection of Antibodies Against the Cellular Protein p53 In Sera from Patients with Breast Cancer", Int. J. Cancer 30, 1982, pp. 403-408.
	Wallner et al., "Cloning and expression of human lipocortin, a phospholipase A.sub.2 inhibitor with potential anti-inflammatory activity", Nature, vol. 320, Mar. 1986, pp. 77-80.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

NY02:506860.1

Form PTO-1449 U.S. Department of Commerce
(REV. 12-82) Patent and Trademark Office

Atty. Docket No.
A31910-1 - 072874.0171

Serial No.
10/656,356

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

Applicants
Hanash et al.

Filing Date
September 5, 2003

Group Art Unit
1641

		Weber et al., "Repeating sequence homologies in the p36 target protein of retroviral protein kinses and lipocortin, the p37 inhibitor of phospholipase A.sub.2 ", FEBS LETTERS, vol. 203, No. 1, Ju 1986, pp. 95-98.
		Saris et al, "The cDNA Sequence for the Protein-Tyrosine Kinase Substrate p36 (Calpactin 1 Heavy Chain) Reveals a Multidomain Protein with Internal Repeats", Cell, vol. 46, Jul. 18, 1986, pp. 201-212.
		Huang et al., "Two Human 35 kd Inhibitors of Phospholipase A.sub.2 Are Related to Substrates o pp60.sup.v-src and of the Epidermal Growth Factor Receptor/Kinase", Cell, vol. 46, Jul. 18, 1986 pp. 191-199.
		Tan et al., "PCNA/Cyclin: A Lupus Antigen Connected with DNA Replication", J. Rheumatol., Supp. 13, vol. 14, 1987, pp. 89-96.
		Ben-Mahrez et al., "Circulating Antibodies Against C-MYC Oncogene Product in Sera of Colorectal Cancer Patients", Int. J. Cancer 46, 1990, pp. 35-38.
		Sorokine et al., "Presence of Circulating Anti-c-myp Oncogene Product Antibodies in Human Sera", Int. J. Cancer: 47, 1991, pp. 665-669.
		Bandorowicz et al., "Annexins--multifunctional, calcium-dependent phosphloipid-binding proteins", Acta Biochimica Polonica, vol. 40, No. 3, 1993, pp. 281-293.
		Swairjo et al., "Annexin Structure and Mebrance Interactions: A Molecular Perspective", Annu. Rev. Biophys. Biomol. Struct. 23, 1994, pp. 193-213.
		Mao et al., "Detection of Oncogene Mutations in Sputum Precedes Diagnosis of Lung Cancer", Cancer Res. 54, Apr. 1, 1994, pp. 1634-1637.
		Liemann et al., "Annexins: a novel family of calcium- and membrane- binding proteins in search of a function", Structure, vol. 3, No. 3, 1995, pp. 233-237.
		Gourevitch et al., "Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patietns", Br. J. Cancer 72, 1995, pp. 934-938.
		Mills et al., "Detection of K-ras Oncogene Mutations in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis", J. Natl. Cancer Inst., vol. 87, No. 14, Jul. 19, 1995, pp. 1056-1060.
		Takahashi et al., "Antibody to ras Proteins in Patients with Colon Cancer", Clin. Cancer Res., vol. 1, Oct. 1995, pp. 1071-1077.
		Peyrate et al., "Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer", Lancet, vol. 345, Mar. 1, 1995, pp. 621-622.

Examiner

Date Considered


* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

NY02:506860.1

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
A31910-I - 072874.0171

Serial No.
10/656,356



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicants
Hanash et al.

Filing Date
September 5, 2003

Group Art Unit
1641

		Lubin et al., "Serum p53 antibodies as early markers of lung cancer", Nat. Med., vol. 1, No. 7, Jul 1995, pp. 701-702.
		Yamamoto et al., "Detection of auto-antibodies against L-myc Oncogene Products in Sera From Lung Cancer Patients", J. Int. Cancer (Pred. Oncol) 69, 1996, pp. 283-289.
		Soussi, "The humoral response to the tumor-suppressor gene product p53 in human cancer: implications for diagnosis and therapy", Immunol. Today, vol. 17, No. 8, pp. 354-356.
		Travis et al., "United States Lung Carcinoma Incidence Trends", Cancer, vol. 77, No. 12, Jun. 15, 1996, pp. 2464-2470.
		Benz et al., "Annexins: From Structure to Function", Biol. Chem., vol. 378, Mar./Apr. 1997, pp. 177-183.
		Gerke et al., "Annexins and membrane dynamics", Biochemica et Biophysica Acta 1357, 1997, pp. 129-154.
		Donnelly et al., "Annexins in the secretory pathway", Cell Mol. Life Sci. 53, 1997, pp. 533-538.
		Mollenhuaer, "Annexins: what are they good for?", Cell Mol. Life Sci. 53, 1997, pp. 506-507.
		Gao et al., "Distribution of p53 and K-ras mutations in human lung cancer tissues", Carcinogenesis, vol. 18, No. 3, 1997, pp. 473-478.
		Old et al., "New Paths in Human Cancer Serology", J.Exp. Med., vol. 187, No. 8, Apr. 20, 1998, pp. 1163-1167.
		Iizasa et al., "Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma", Cancer Immunol. Immunother. 46, 1998, pp. 345-349.
		Stockert et al., "A survey of the humoral immune response of cancer patients to a panel of human tumor antigens", J. Exp. Med. 187, 1998, pp. 1349-1354.
		Gure et al., "Human Lung Cancer Antigens Recognized by Autologous Antibodies: Definition of Novel cDNA Derived from the Tumor Suppressor Gene Locus on Chromosome 3p21.3", Cancer Res. 58, Mar. 1, 1998, pp. 1034-1041.
		Cawley et al., "Anti-p53 Antibodies in Patients with Barrett's Esophagus or Esophageal Carcinoma Can Precede Cancer Diagnosis", Gastroenterology, vol. 115, No. 1, 1998, pp. 19-27.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

NY02:506860.1

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
A31910-I - 072874.0171

Serial No.
10/656,356

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicants
Hanash et al.

Filing Date
September 5, 2003

Group Art Unit
1641



Pencil et al., "Elevated Levels of Annexin I Protein in Vitro and In Vivo in Rat and Human Mammary Adenocarcinoma", 1998, Clin. Exp. Metastasis 16:113-121.

Davis et al., "Detection of Secreted and Intracellular Annexin II by a Radiomunoassay", 1995, Journal of Immunological Methods 188: 91-95.

Tsao et al., "Annexin I in Female Rabbit Reproductive Organs: Varying Levels in Relation to Maturity and Pregnancy", 1995, Lipids 30: 507-511.

William et al., "Differentiation of HL-60 Cells is Associated with an Increase in the 35-KDa Protein Lipocortin I", 1988, J. Cellular Physiology 137: 402-410.

Bastian et al., "Autoantibodies to annexins: a diagnostic marker for cutaneous disorders?", 1994, Journal of Dermatological Science 8: 194-202.

Pupa et al., "Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients", 1993, Cancer Research 53: 5864-5866.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

NY02:506860.1